Oncoteq

Executive Summary

Oncoteq is a clinical-stage oncology biotech based in Zug, Switzerland, founded in 2022 with a lean team of 1–10 employees. The company uses a proprietary AI platform to identify optimal therapeutic applications for molecules, thereby de-risking clinical development. Its pipeline includes three first-in-class or best-in-class candidates targeting high-unmet-need cancers. By focusing on unattended oncology assets, Oncoteq aims to unlock hidden value and advance assets efficiently through a low-cost, agile operational model. The company is currently in Phase 1 development and operates as a private entity with no disclosed funding or valuation.

Upcoming Catalysts (preview)

• TBDPhase 1 data readout for lead candidate40% success
• TBDStrategic partnership or licensing deal for AI platform30% success
• TBDSeries A financing round50% success